GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides
Technical presentation · July 30, 2026
A technical presenter reviewed quality and "sameness" considerations for generic oligonucleotide drugs, focusing on chemical modifications, diastereomeric complexity, impurity risks, analytical-method limits, and regulatory implications for ANDA submissions under Hatch-Waxman rules.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.